The fight is heating up in the push to reform the federal 340B drug discount program to reduce the out-of-pocket costs to Medicare enrollees and other participants. The pharmaceutical industry is now weighing in on rising out-of-pocket costs due to 340B hospitals shifting patients to more expensive sites of care.
An analysis of Medicare Fee-for-Service claims data by the Berkeley Research Group shows a substantial shift in site of care for outpatient drug therapies from the physician office to the 340B hospital outpatient setting from 2008 to 2015, according to the report, "Site of Care Shift for Physician-Administered Drug Therapies," commissioned by the Pharmaceutical Research and Manufacturers of America.
For breast cancer and multiple myeloma medicines, about 33 percent of all Part B sales were at 340B hospitals by 2015, compared to 11 or 12 percent in 2008. About 19 percent of the rheumatoid arthritis drug sales through Part B were to 340B hospitals in 2015, compared to 6 percent in 2008.
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Katie Kuehner-Hebert
Katie Kuehner-Hebert is a freelance writer based in Running Springs, Calif. She has more than three decades of journalism experience, with particular expertise in employee benefits and other human resource topics.
